GlassScriptPhysician profile
Jolene Garrow
NPI 1881466886
$2,094.21
in general payments reported to CMS, 2019-2025
19 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $153 · 2024: $1,303 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $551.59 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $318.27 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $285.86 | 2023-2025 | Spravato |
| Axsome Therapeutics, INC. | $151.90 | 2024-2025 | Auvelity |
| Lundbeck LLC | $118.55 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $110.28 | 2024-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.81 | 2024-2025 | Caplyta |
| Almatica Pharma LLC | $75.40 | 2024-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $74.02 | 2024-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $57.31 | 2025 | Jornay Pm |
| Tris Pharma INC | $56.86 | 2024-2025 | Dyanavel Xr |
| Alkermes, INC. | $39.18 | 2024 | Lybalvi, Aristada |
| Harmony Biosciences LLC | $35.24 | 2024 | |
| Neos Therapeutics, LP | $33.94 | 2024-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Corium, LLC | $29.33 | 2025 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.31 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $16.42 | 2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $15.29 | 2025 | Austedo Xr |
| Noven Therapeutics, LLC | $14.65 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolene Garrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.